ANCHIANO THERAP/S’s (NASDAQ:ANCN) lock-up period will end on Monday, August 12th. ANCHIANO THERAP/S had issued 2,652,174 shares in its IPO on February 12th. The total size of the offering was $30,500,001 based on an initial share price of $11.50. After the expiration of the company’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Several equities research analysts have recently commented on ANCN shares. Robert W. Baird started coverage on ANCHIANO THERAP/S in a report on Tuesday, May 28th. They set an “outperform” rating and a $12.00 price objective for the company. ValuEngine upgraded ANCHIANO THERAP/S from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research upgraded ANCHIANO THERAP/S from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a report on Friday. Five research analysts have rated the stock with a buy rating, ANCHIANO THERAP/S presently has an average rating of “Buy” and an average target price of $10.42.

NASDAQ ANCN opened at $2.69 on Monday. The company has a market capitalization of $20.85 million and a P/E ratio of -0.51. ANCHIANO THERAP/S has a 52 week low of $2.53 and a 52 week high of $11.50. The firm’s 50 day moving average price is $4.02.

ANCHIANO THERAP/S (NASDAQ:ANCN) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.05) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.11. As a group, sell-side analysts expect that ANCHIANO THERAP/S will post -1.94 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. Delek Group Ltd. bought a new stake in ANCHIANO THERAP/S during the first quarter worth $176,000. Meitav Dash Investments Ltd. bought a new stake in ANCHIANO THERAP/S during the first quarter worth $177,000. Kennedy Capital Management Inc. bought a new stake in ANCHIANO THERAP/S during the first quarter worth $1,359,000. Finally, FMR LLC bought a new stake in ANCHIANO THERAP/S during the first quarter worth $288,000. Institutional investors and hedge funds own 6.18% of the company’s stock.

ANCHIANO THERAP/S Company Profile

Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd.

Read More: Insider Trading – What You Need to Know

Receive News & Ratings for ANCHIANO THERAP/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANCHIANO THERAP/S and related companies with MarketBeat.com's FREE daily email newsletter.